Results 251 to 260 of about 105,796 (273)

MIF downregulation attenuates neuroinflammation via TLR4/MyD88/TRAF6/NF-κB pathway to protect dopaminergic neurons in Parkinson's disease model. [PDF]

Commun Biol
Huang Y, Zhou C, Qu S.
europepmc   +1 more source

Increased Toll-Like Receptor-4 Signalling in Breast Tissue of High Fibroglandular Density. [PDF]

J Mammary Gland Biol Neoplasia
Heydarlou H, Hodson LJ, Dasari P, Smith E, Ingman WV.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Oncogenic MyD88

Science Signaling, 2011
A gain-of-function mutation in MyD88 promotes survival of a B cell lymphoma through activation of NF-κB and JAK-STAT signaling pathways.
openaire   +1 more source

Atg5 regulates formation of MyD88 condensed structures and MyD88-dependent signal transduction

Biochemical and Biophysical Research Communications, 2013
MyD88 is known as an essential adaptor protein for Toll-like receptors (TLRs). Previous studies have shown that transfected MyD88 forms condensed structures in the cytoplasm. However, upon TLR stimulation, there is little formation of endogenous MyD88 condensed structures. Thus, the formation of MyD88 condensed structures is tightly suppressed, but the
Megumi, Inomata, Takeshi, Into, Shumpei, Niida, Yukitaka, Murakami   +3 more
openaire   +2 more sources

Mighty Deadly MyD88

Science's STKE, 2000
Toll receptors are activated by bacterially produced pathogen-associated molecular pattern (PAMPs). Bacterial lipoproteins (BLPs) are PAMPs that activate the Toll-like receptor 2 (TLR2) through recruitment of the adaptor molecule MyD88. Transfection of a variety of dominant negative mutants allowed Aliprantis et al
openaire   +2 more sources

MyD88 beyond Toll

Nature Immunology, 2006
The adaptor protein MyD88 is involved in interleukin 1 receptor and Toll-like receptor signaling. Unexpectedly, new evidence shows that MyD88 also participates in interferon-γ-induced cellular responses.
openaire   +1 more source

MYD88 L265P mutation in Waldenstrom macroglobulinemia

Blood, 2013
Key Points The MYD88 locus is altered in 91% of patients with WM. MYD88 might be new target for therapeutic in WM.
Stéphanie, Poulain, Christophe, Roumier, Audrey, Decambron, Aline, Renneville, Charles, Herbaux, Elisabeth, Bertrand, Sabine, Tricot, Agnès, Daudignon, Sylvie, Galiègue-Zouitina, Valerie, Soenen, Olivier, Theisen, Nathalie, Grardel, Olivier, Nibourel, Catherine, Roche-Lestienne, Bruno, Quesnel, Patrick, Duthilleul, Claude, Preudhomme, Xavier, Leleu   +17 more
openaire   +2 more sources

Mycobacterial Infection in MyD88‐Deficient Mice

Microbiology and Immunology, 2003
AbstractMyD88 is an adaptor protein that plays a major role in TLR/IL‐1 receptor family signaling. To understand the role of MyD88 in the development of murine tuberculosis in vivo, MyD88 knockout (KO) mice aerially were infected with Mycobacterium tuberculosis. Infected MyD88 mice were not highly susceptible to M.
Isamu, Sugawara, Hiroyuki, Yamada, Satoru, Mizuno, Kiyoshi, Takeda, Shizuo, Akira   +4 more
openaire   +2 more sources

Mighty MyD88 in Health and Disease

Retina, 2016
In 2012, Treon et al,1 in their study of patients with IgM lymphoplasmacytic lymphoma and the associated clinical syndrome Waldenstrom macroglobulinemia (WM), found that a single nucleotide somatic mutation in the myeloid differentiation primary response 88 (MYD88) gene, leading to ...
Jose S, Pulido, Harish, Raja, Richard G, Vile, Diva R, Salomao, David S, Viswanatha   +4 more
openaire   +2 more sources

Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia

Leukemia, 2016
MYD88 (myeloid differentiation primary response 88) is mutated in the majority of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (LPL); but also, albeit less frequently, in other B-cell malignancies, including chronic lymphocytic leukemia (CLL).
C, Baer, F, Dicker, W, Kern, T, Haferlach, C, Haferlach   +4 more
openaire   +2 more sources